首页 > 最新文献

Medical Journal of Australia最新文献

英文 中文
Mental health training for physicians supervising resident physicians: a cluster randomised controlled trial 对指导住院医生的医生进行心理健康培训:分组随机对照试验。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-08-16 DOI: 10.5694/mja2.52407
Aimée Gayed, Jessica Strudwick, Nathasha Kugenthiran, Anthony D LaMontagne, Andrew Mackinnon, Helen Christensen, Nicholas Glozier, Samuel Harvey
<div> <section> <h3> Objective</h3> <p>To evaluate an online training program for physician supervisors with the aim of promoting a mentally healthy workplace by improving their use of both responsive and preventive mental health support strategies.</p> </section> <section> <h3> Study design</h3> <p>Cluster randomised, waitlist-controlled trial.</p> </section> <section> <h3> Setting, participants</h3> <p>Royal Australasian College of Physicians fellows who were supervising at least one resident physician in any of the 31 primary health networks in Australia and 20 district health boards in New Zealand (health network clusters).</p> </section> <section> <h3> Intervention</h3> <p>A brief online skills-based mental health training program, comprising twelve modules grouped into three topics: common mental illnesses; helping trainees you are concerned about (responsive strategies); and minimising mental health risks at work (preventive strategies).</p> </section> <section> <h3> Main outcome measures</h3> <p>Change between baseline and the 3-month assessment in self-reported recommended supervisor behaviours; differences between intervention and control groups in recommended behaviour scores three weeks, three months, and six months after the program.</p> </section> <section> <h3> Results</h3> <p>Ninety physicians from 20 health network clusters were allocated to the intervention group, 88 physicians from 22 clusters to the control group. Intervention group participants reported greater positive change in behaviour across the study period than those in the control group (mixed model repeated measures analysis, group × time interaction: <i>P</i> < 0.001). The mean change in self-reported supervisory behaviour score was higher for the intervention than the control group at the 3-week (mean difference in score, 1.6; 95% confidence interval [CI], 0.8–2.4), 3-month (0.9; 95% CI, 0.2–1.6), and 6-month assessments (1.9; 95% CI, 1.1–2.7). The mean change in self-reported responsive behaviour score was also greater for the intervention group at the 3-week (mean difference, 2.3; 95% CI, 1.5–3.1), 3-month (1.0; 95% CI, 0.2–1.9), and 6-month assessments (2.0; 95% CI, 1.1–2.9); differences in the mean change in preventive behaviour scores were statistically significant at the 3-week (mean difference, 1.1; 95% CI, 0.1–2.2) and 6-month assessments (1.8; 95% CI, 0.8
目的:评估一项针对医生主管的在线培训计划,旨在通过提高他们对响应性和预防性心理健康支持策略的使用,促进心理健康工作场所:对一项针对医生主管的在线培训项目进行评估,目的是通过提高他们对响应性和预防性心理健康支持策略的使用,促进心理健康的工作场所:分组随机、候补名单对照试验:澳大拉西亚皇家内科医学院研究员,他们在澳大利亚 31 个初级卫生网络和新西兰 20 个地区卫生局(卫生网络群)中的任何一个网络中指导至少一名住院医师:干预措施:基于技能的简短在线心理健康培训项目,包括十二个模块,分为三个主题:常见心理疾病;帮助您所关注的学员(应对策略);以及最大限度地降低工作中的心理健康风险(预防策略):主要结果测量:基线与 3 个月评估之间自我报告的主管推荐行为的变化;干预组与对照组在课程结束后 3 周、3 个月和 6 个月推荐行为得分的差异:来自 20 个医疗网络集群的 90 名医生被分配到干预组,来自 22 个集群的 88 名医生被分配到对照组。与对照组相比,干预组的参与者在整个研究期间的行为发生了更大的积极变化(混合模型重复测量分析,组别 × 时间交互作用):P 结论:对高年资医师进行简短的在线心理健康培训可以改变他们自我报告的支持住院医师心理健康需求的行为。试验注册:试验注册:澳大利亚-新西兰临床试验注册中心,ACTRN12619001496101(前瞻性)。
{"title":"Mental health training for physicians supervising resident physicians: a cluster randomised controlled trial","authors":"Aimée Gayed,&nbsp;Jessica Strudwick,&nbsp;Nathasha Kugenthiran,&nbsp;Anthony D LaMontagne,&nbsp;Andrew Mackinnon,&nbsp;Helen Christensen,&nbsp;Nicholas Glozier,&nbsp;Samuel Harvey","doi":"10.5694/mja2.52407","DOIUrl":"10.5694/mja2.52407","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To evaluate an online training program for physician supervisors with the aim of promoting a mentally healthy workplace by improving their use of both responsive and preventive mental health support strategies.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Study design&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Cluster randomised, waitlist-controlled trial.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Setting, participants&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Royal Australasian College of Physicians fellows who were supervising at least one resident physician in any of the 31 primary health networks in Australia and 20 district health boards in New Zealand (health network clusters).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Intervention&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A brief online skills-based mental health training program, comprising twelve modules grouped into three topics: common mental illnesses; helping trainees you are concerned about (responsive strategies); and minimising mental health risks at work (preventive strategies).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Main outcome measures&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Change between baseline and the 3-month assessment in self-reported recommended supervisor behaviours; differences between intervention and control groups in recommended behaviour scores three weeks, three months, and six months after the program.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Ninety physicians from 20 health network clusters were allocated to the intervention group, 88 physicians from 22 clusters to the control group. Intervention group participants reported greater positive change in behaviour across the study period than those in the control group (mixed model repeated measures analysis, group × time interaction: &lt;i&gt;P&lt;/i&gt; &lt; 0.001). The mean change in self-reported supervisory behaviour score was higher for the intervention than the control group at the 3-week (mean difference in score, 1.6; 95% confidence interval [CI], 0.8–2.4), 3-month (0.9; 95% CI, 0.2–1.6), and 6-month assessments (1.9; 95% CI, 1.1–2.7). The mean change in self-reported responsive behaviour score was also greater for the intervention group at the 3-week (mean difference, 2.3; 95% CI, 1.5–3.1), 3-month (1.0; 95% CI, 0.2–1.9), and 6-month assessments (2.0; 95% CI, 1.1–2.9); differences in the mean change in preventive behaviour scores were statistically significant at the 3-week (mean difference, 1.1; 95% CI, 0.1–2.2) and 6-month assessments (1.8; 95% CI, 0.8","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52407","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gender affirmation testosterone therapy, Australia, 2021–22: a review of PBS dispensing data 澳大利亚 2021-22 年性别确认睾酮疗法:PBS 配药数据审查。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-08-16 DOI: 10.5694/mja2.52415
Brendan J Nolan, Sav Zwickl, Jeffrey D Zajac, Ada S Cheung
<p>In Australia, as overseas, the number of transgender and gender-diverse (trans) people seeking hormone therapy for gender affirmation is increasing.<span><sup>1</sup></span> By aligning a person's physical characteristics with their gender identity, such therapy improves psychological wellbeing, reducing gender dysphoria and depression and improving quality of life.<span><sup>2, 3</sup></span> It is unknown how many trans people use testosterone therapy for gender affirmation in Australia.</p><p>The costs of medications for most medical conditions are subsidised for Australians by the federal government Pharmaceutical Benefits Scheme (PBS). Some medications, including testosterone, require PBS Authorities approval (“authority prescription”). As the PBS does not list gender affirmation as an indication for prescribing testosterone, clinicians use the authority indication “androgen deficiency due to an established pituitary or testicular disorder”, regardless of gender identity markers, in accordance with national guidelines.<span><sup>4</sup></span></p><p>Our aim was to estimate the number of trans people who received PBS-subsidised testosterone for gender affirmation in Australia during 1 July 2021 – 30 June 2022. Our request for PBS dispensing data was approved by the Services Australia External Request Evaluation Committee (RMS2527). The number of people supplied testosterone (item codes 10378F, 08830R, 08619P, 11740X, 10380H, 02115H, 10205D) by age group at 30 June 2022 was provided in aggregate, deidentified form. The testosterone formulations prescribed for trans people to increase testosterone concentrations to the male reference range (10–30 nmol/L) are the same as those used to treat men with hypogonadism.<span><sup>4</sup></span> The proportion of people to whom testosterone was dispensed for whom a current or past female gender marker was recorded was determined by Services Australia; we interpreted a current or past female gender marker as a surrogate marker for a trans man.</p><p>Of the 38 633 people dispensed PBS-subsidised testosterone during 1 July 2021 – 30 June 2022, current or past female gender markers were recorded for 6998 (18%). The proportion differed markedly by age group: 6394 of 10 805 people aged 40 years or younger had current or past female gender markers (59%), including 3795 of 4726 people aged 16–25 years (80%), but only 33 of 12 114 people over 65 years of age (0.3%) (Box).</p><p>We suspect that trans people probably comprised a substantial proportion of the Australians dispensed PBS-subsidised testosterone during 2021–22, particularly among those under 40 years of age. As there are no specific PBS items for gender affirmation treatment, people seeking medical gender affirmation may remain untreated or pay for it themselves, potentially limiting access. A specific PBS authority indication for “gender affirmation” is needed, ideally without requiring consultation with a specialist, to monitor prescribing activit
1 通过使一个人的身体特征与其性别认同相一致,这种疗法可以改善心理健康,减少性别焦虑症和抑郁症,提高生活质量。2, 3 目前尚不清楚在澳大利亚有多少变性人使用睾酮疗法来确认性别。包括睾酮在内的一些药物需要获得 PBS 当局的批准("当局处方")。4 我们的目的是估算出 2021 年 7 月 1 日至 2022 年 6 月 30 日期间,澳大利亚因性别确认而接受 PBS 补贴的睾酮治疗的变性人数量。4 我们的目的是估算 2021 年 7 月 1 日至 2022 年 6 月 30 日期间,在澳大利亚接受 PBS 补贴的睾酮治疗的变性人数量。截至 2022 年 6 月 30 日,按年龄组提供睾酮(项目代码 10378F、08830R、08619P、11740X、10380H、02115H、10205D)的人数以汇总和去标识形式提供。为将变性人的睾酮浓度提高到男性参考值范围(10-30 nmol/L)而开具的睾酮制剂与用于治疗性腺功能减退症男性的制剂相同。在 2021 年 7 月 1 日至 2022 年 6 月 30 日期间,38 633 人获得了 PBS 补贴的睾酮,其中 6 998 人(18%)记录了当前或过去的女性性别标记。各年龄组的比例差异显著:年龄在 40 岁或以下的 10 805 人中,有 6394 人目前或过去有女性性别标记(59%),包括年龄在 16-25 岁的 4726 人中的 3795 人(80%),但年龄在 65 岁以上的 12 114 人中只有 33 人(0.3%)(方框)。由于没有针对性别确认治疗的特定 PBS 项目,寻求医疗性别确认的人可能得不到治疗或需自行支付费用,这可能会限制其获得治疗的机会。作为分析的局限性,我们注意到我们无法确定处方的连续性或标签外处方。数据集可能还包括性发育有差异者,或患有垂体功能减退症和性欲减退症(雄激素缺乏症)的女性;不过,在澳大利亚,后一种适应症通常使用无补贴的低剂量睾酮制剂(AndroFeme5)。目前的数据无法提供对使用睾酮进行性别确认的变性人数量的具体评估。公共医疗卫生服务机构对 "性别确认 "的具体指征将提供准确的评估,以指导服务的提供并提高护理质量。[首次在线发表后,于 2024 年 8 月 28 日添加更正:墨尔本大学通过澳大利亚大学图书馆员理事会达成的 Wiley - 墨尔本大学协议的一部分,为开放存取出版提供了便利。
{"title":"Gender affirmation testosterone therapy, Australia, 2021–22: a review of PBS dispensing data","authors":"Brendan J Nolan,&nbsp;Sav Zwickl,&nbsp;Jeffrey D Zajac,&nbsp;Ada S Cheung","doi":"10.5694/mja2.52415","DOIUrl":"10.5694/mja2.52415","url":null,"abstract":"&lt;p&gt;In Australia, as overseas, the number of transgender and gender-diverse (trans) people seeking hormone therapy for gender affirmation is increasing.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; By aligning a person's physical characteristics with their gender identity, such therapy improves psychological wellbeing, reducing gender dysphoria and depression and improving quality of life.&lt;span&gt;&lt;sup&gt;2, 3&lt;/sup&gt;&lt;/span&gt; It is unknown how many trans people use testosterone therapy for gender affirmation in Australia.&lt;/p&gt;&lt;p&gt;The costs of medications for most medical conditions are subsidised for Australians by the federal government Pharmaceutical Benefits Scheme (PBS). Some medications, including testosterone, require PBS Authorities approval (“authority prescription”). As the PBS does not list gender affirmation as an indication for prescribing testosterone, clinicians use the authority indication “androgen deficiency due to an established pituitary or testicular disorder”, regardless of gender identity markers, in accordance with national guidelines.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Our aim was to estimate the number of trans people who received PBS-subsidised testosterone for gender affirmation in Australia during 1 July 2021 – 30 June 2022. Our request for PBS dispensing data was approved by the Services Australia External Request Evaluation Committee (RMS2527). The number of people supplied testosterone (item codes 10378F, 08830R, 08619P, 11740X, 10380H, 02115H, 10205D) by age group at 30 June 2022 was provided in aggregate, deidentified form. The testosterone formulations prescribed for trans people to increase testosterone concentrations to the male reference range (10–30 nmol/L) are the same as those used to treat men with hypogonadism.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; The proportion of people to whom testosterone was dispensed for whom a current or past female gender marker was recorded was determined by Services Australia; we interpreted a current or past female gender marker as a surrogate marker for a trans man.&lt;/p&gt;&lt;p&gt;Of the 38 633 people dispensed PBS-subsidised testosterone during 1 July 2021 – 30 June 2022, current or past female gender markers were recorded for 6998 (18%). The proportion differed markedly by age group: 6394 of 10 805 people aged 40 years or younger had current or past female gender markers (59%), including 3795 of 4726 people aged 16–25 years (80%), but only 33 of 12 114 people over 65 years of age (0.3%) (Box).&lt;/p&gt;&lt;p&gt;We suspect that trans people probably comprised a substantial proportion of the Australians dispensed PBS-subsidised testosterone during 2021–22, particularly among those under 40 years of age. As there are no specific PBS items for gender affirmation treatment, people seeking medical gender affirmation may remain untreated or pay for it themselves, potentially limiting access. A specific PBS authority indication for “gender affirmation” is needed, ideally without requiring consultation with a specialist, to monitor prescribing activit","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52415","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Calling time on the use of modified-release opioids for acute pain 为使用缓释型阿片类药物治疗急性疼痛设定时间。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-08-16 DOI: 10.5694/mja2.52417
Pamela E Macintyre, Melissa A Jamcotchian, Jennifer A Stevens
<p>The first modified-release (MR) formulation of oxycodone was approved for the management of pain in 1995 and aggressively marketed (with false claims of a low addiction risk) primarily for the management of chronic non-cancer pain.<span><sup>1</sup></span> In many high income countries, including Australia,<span><sup>2</sup></span> prescription of MR oxycodone for the management of acute pain, especially post-operative pain, then became commonplace.<span><sup>1</sup></span> This occurred despite no evidence at the time showing that MR oxycodone was better — in terms of analgesia and/or adverse effects — than immediate-release (IR) oxycodone alone (as explained below).<span><sup>1, 3, 4</sup></span> A survey of Australian public and private hospital pharmacists showed that MR opioids were commonly prescribed to opioid-naïve patients with acute pain in more than 70% of hospitals — both as an inpatient and at discharge.<span><sup>2</sup></span></p><p>Guidelines reflecting the current evidence base and aiming to improve the safety of opioid use for acute pain management in Australia have recently been introduced.<span><sup>5, 6</sup></span> These strongly recommend against the initiation of MR opioids for acute pain in opioid-naïve patients. Opioids remain an important part of multimodal acute pain analgesic regimens, with guidelines indicating how to use IR opioids more safely and effectively, while not limiting appropriate access and dosing for patients who require them.</p><p>Calling time on initiating MR opioids for acute pain is a key recommendation of these guidelines and aims to reduce opioid risk in two key areas: in-hospital morbidity and mortality, and inadvertent persistent post-discharge opioid use (PPOU), which comes with its own list of potential adverse effects.<span><sup>7</sup></span></p><p>In 2000, regulatory changes made by the Australian Therapeutics Goods Administration were designed to decrease the risk of harm from prescription opioids.<span><sup>8</sup></span> Included in the changes were that MR opioids should not be used for the management of severe pain unless the pain is opioid-responsive and “requires daily, continuous, long term treatment” (thus excluding acute pain).<span><sup>8</sup></span> In 2022, the Australian Commission on Safety and Quality in Health Care published their Opioid Analgesic Stewardship in Acute Pain Clinical Care Standards, which advised that MR opioid use for the management of acute pain “should be exceptional and not routine”.<span><sup>5</sup></span> In the same year, a new Choosing Wisely Australia statement said “Avoid routine prescription of slow-release (SR) opioids in the management of acute pain, in hospital and community settings, unless there is a demonstrated need, close monitoring is available, and a cessation plan is in place”.<span><sup>9</sup></span> A 2023 publication from the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine contains similar recomm
未经委托;外部同行评审。
{"title":"Calling time on the use of modified-release opioids for acute pain","authors":"Pamela E Macintyre,&nbsp;Melissa A Jamcotchian,&nbsp;Jennifer A Stevens","doi":"10.5694/mja2.52417","DOIUrl":"10.5694/mja2.52417","url":null,"abstract":"&lt;p&gt;The first modified-release (MR) formulation of oxycodone was approved for the management of pain in 1995 and aggressively marketed (with false claims of a low addiction risk) primarily for the management of chronic non-cancer pain.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; In many high income countries, including Australia,&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; prescription of MR oxycodone for the management of acute pain, especially post-operative pain, then became commonplace.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; This occurred despite no evidence at the time showing that MR oxycodone was better — in terms of analgesia and/or adverse effects — than immediate-release (IR) oxycodone alone (as explained below).&lt;span&gt;&lt;sup&gt;1, 3, 4&lt;/sup&gt;&lt;/span&gt; A survey of Australian public and private hospital pharmacists showed that MR opioids were commonly prescribed to opioid-naïve patients with acute pain in more than 70% of hospitals — both as an inpatient and at discharge.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Guidelines reflecting the current evidence base and aiming to improve the safety of opioid use for acute pain management in Australia have recently been introduced.&lt;span&gt;&lt;sup&gt;5, 6&lt;/sup&gt;&lt;/span&gt; These strongly recommend against the initiation of MR opioids for acute pain in opioid-naïve patients. Opioids remain an important part of multimodal acute pain analgesic regimens, with guidelines indicating how to use IR opioids more safely and effectively, while not limiting appropriate access and dosing for patients who require them.&lt;/p&gt;&lt;p&gt;Calling time on initiating MR opioids for acute pain is a key recommendation of these guidelines and aims to reduce opioid risk in two key areas: in-hospital morbidity and mortality, and inadvertent persistent post-discharge opioid use (PPOU), which comes with its own list of potential adverse effects.&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;In 2000, regulatory changes made by the Australian Therapeutics Goods Administration were designed to decrease the risk of harm from prescription opioids.&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt; Included in the changes were that MR opioids should not be used for the management of severe pain unless the pain is opioid-responsive and “requires daily, continuous, long term treatment” (thus excluding acute pain).&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt; In 2022, the Australian Commission on Safety and Quality in Health Care published their Opioid Analgesic Stewardship in Acute Pain Clinical Care Standards, which advised that MR opioid use for the management of acute pain “should be exceptional and not routine”.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; In the same year, a new Choosing Wisely Australia statement said “Avoid routine prescription of slow-release (SR) opioids in the management of acute pain, in hospital and community settings, unless there is a demonstrated need, close monitoring is available, and a cessation plan is in place”.&lt;span&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/span&gt; A 2023 publication from the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine contains similar recomm","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52417","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The loneliness epidemic: a holistic view of its health and economic implications in older age 孤独流行病:对老年人健康和经济影响的整体看法。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-08-15 DOI: 10.5694/mja2.52414
Lidia Engel, Cathrine Mihalopoulos
<p>Loneliness has been described as an epidemic and is one of the most pressing public health concerns in Australia and internationally.<span><sup>1, 2</sup></span> In contrast to social isolation, which is an objective measure of social interactions and relationships, loneliness is defined as a subjective experience where one perceives a discrepancy between desired and actual social relationships in terms of quality or quantity.<span><sup>3</sup></span> Although it is common and natural to feel lonely at times, prolonged and intense periods of loneliness have been linked to adverse health outcomes.<span><sup>4</sup></span> Older adults are more prone to loneliness and social isolation compared with other age groups.<span><sup>5</sup></span> Reasons for this include significant life transitions and events, such as retiring from work, increased financial difficulties, loss of friends and widowhood, changes in living arrangements (eg, transitioning to residential aged care), increase in solitary living, and a decline in both health and independence.<span><sup>5, 6</sup></span> Older people at particular risk of loneliness include those living on low incomes, living with a disability, living in rural areas or with housing stress, who are single, childless or living alone, who are vulnerable or at risk of elder abuse, and those with low levels of literacy or communication technology skills (Box).<span><sup>7</sup></span> A growing body of evidence has highlighted the significant health burden associated with loneliness, with more recent studies also suggesting that loneliness has become an economic problem due to an increase in service use and demand for institutional care. This development requires both effective and cost-effective strategies to tackle loneliness.<span><sup>11, 12</sup></span></p><p>A recent meta-analysis found that 28.5% of older people aged 60 years and above experience some degree of loneliness.<span><sup>13</sup></span> Although the study did not observe that loneliness is more common in people aged over 75 years than in those aged 65–75 years, other studies have found that the old (75–84 years) and oldest old (≥ 85 years) are more affected by loneliness than the youngest old (65–74 years).<span><sup>1, 14</sup></span> The prevalence of loneliness among institutionalised older adults is less well documented but a recent meta-analysis estimated the mean prevalence of moderate and severe loneliness in older people living in care homes at 61% and 35% respectively.<span><sup>15</sup></span> Determining the prevalence of loneliness remains a challenge due to its subjective nature, the stigma attached to it, and measurement problems. The use of a direct, single-question measure of loneliness appears to be commonly applied in national surveys and research studies because it is simple and generates fewer missing values. On the flip side, such measures are prone to ambiguous interpretation of the term loneliness and under-reporting due t
这包括关注不同文化和语言社区的需求,并确保对不同群体的包容,如女同性恋者、男同性恋者、双性恋者和变性老年人。了解孤独的主观性和异质性也很重要,强调需要更好地了解老年人的孤独生活经历。认识到没有放之四海而皆准的方法,服务的提供和实施需要根据社区的需要和消费者的偏好量身定制,采取以人为本的方法,包括让有生活经验的老年人参与干预措施的设计。此外,还需要一个整体性的优先事项设定框架,以便在决定向何处投资、采取何种干预措施以及以谁为目标时提供可操作的见解,同时要求提供解决孤独问题的干预措施的有效性和成本效益证据。
{"title":"The loneliness epidemic: a holistic view of its health and economic implications in older age","authors":"Lidia Engel,&nbsp;Cathrine Mihalopoulos","doi":"10.5694/mja2.52414","DOIUrl":"10.5694/mja2.52414","url":null,"abstract":"&lt;p&gt;Loneliness has been described as an epidemic and is one of the most pressing public health concerns in Australia and internationally.&lt;span&gt;&lt;sup&gt;1, 2&lt;/sup&gt;&lt;/span&gt; In contrast to social isolation, which is an objective measure of social interactions and relationships, loneliness is defined as a subjective experience where one perceives a discrepancy between desired and actual social relationships in terms of quality or quantity.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Although it is common and natural to feel lonely at times, prolonged and intense periods of loneliness have been linked to adverse health outcomes.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; Older adults are more prone to loneliness and social isolation compared with other age groups.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; Reasons for this include significant life transitions and events, such as retiring from work, increased financial difficulties, loss of friends and widowhood, changes in living arrangements (eg, transitioning to residential aged care), increase in solitary living, and a decline in both health and independence.&lt;span&gt;&lt;sup&gt;5, 6&lt;/sup&gt;&lt;/span&gt; Older people at particular risk of loneliness include those living on low incomes, living with a disability, living in rural areas or with housing stress, who are single, childless or living alone, who are vulnerable or at risk of elder abuse, and those with low levels of literacy or communication technology skills (Box).&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; A growing body of evidence has highlighted the significant health burden associated with loneliness, with more recent studies also suggesting that loneliness has become an economic problem due to an increase in service use and demand for institutional care. This development requires both effective and cost-effective strategies to tackle loneliness.&lt;span&gt;&lt;sup&gt;11, 12&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;A recent meta-analysis found that 28.5% of older people aged 60 years and above experience some degree of loneliness.&lt;span&gt;&lt;sup&gt;13&lt;/sup&gt;&lt;/span&gt; Although the study did not observe that loneliness is more common in people aged over 75 years than in those aged 65–75 years, other studies have found that the old (75–84 years) and oldest old (≥ 85 years) are more affected by loneliness than the youngest old (65–74 years).&lt;span&gt;&lt;sup&gt;1, 14&lt;/sup&gt;&lt;/span&gt; The prevalence of loneliness among institutionalised older adults is less well documented but a recent meta-analysis estimated the mean prevalence of moderate and severe loneliness in older people living in care homes at 61% and 35% respectively.&lt;span&gt;&lt;sup&gt;15&lt;/sup&gt;&lt;/span&gt; Determining the prevalence of loneliness remains a challenge due to its subjective nature, the stigma attached to it, and measurement problems. The use of a direct, single-question measure of loneliness appears to be commonly applied in national surveys and research studies because it is simple and generates fewer missing values. On the flip side, such measures are prone to ambiguous interpretation of the term loneliness and under-reporting due t","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52414","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141982749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
“Social prescribing” another stolen Indigenous concept? "社会处方 "是另一个被盗用的土著概念?
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-08-14 DOI: 10.5694/mja2.52413
Uday N Yadav, Rosemary Wyber, Fiona Cornforth (Wuthathi/Maluilgal), Raymond W Lovett (Wongaibon/Ngiyampaa)

To the Editor: Holistic comprehensive care is the core of community-controlled primary care services for Aboriginal and Torres Strait Islander peoples. To achieve this, Aboriginal and Torres Strait Islander community-controlled health organisations (ACCHOs) have routinely delivered or connected people using these services since 1971 to address the myriad of socio-economic and cultural determinants through a caring approach rooted in Indigenous knowledge and practices.1 In addition to biomedical and allied health referrals, ACCHOs broker and provide a suite of social and cultural connections with housing, education and legal aid services.2 This connected, comprehensive model of care is the core business of ACCHOs, and it does not have a special name.

Internationally, and in Australia, there is a growing focus on social prescribing programs. Social prescribing has been described as “pioneered” in the United Kingdom during the 1980s–1990s and provides a formal process for primary health care workers to connect patients to a wide range of non-clinical services and supports tailored to their needs.3 These encompass healthy lifestyle support services, financial assistance, housing and community gardening, ultimately enhancing health and wellbeing.4 There has been a surge in social prescribing research and policy interest globally. However, the ACCHO model has been delivering holistic care for patients and the community with a more sustainable workforce model that needs to be recognised, celebrated, replicated and shared nationally and globally.

A common feature of settler colonialism is the appropriation of lands, knowledge and concepts in the name of discovery.5 This supplanting of holistic care with social prescribing is another demonstration of the continuing settler colonial approach, where the Aboriginal and Torres Strait Islander holistic model has been erased and reframed as social prescribing. There has been scant acknowledgement that social prescribing has been happening in ACCHOs across Australia for decades. A national funding model must be developed to adequately support the ACCHO sector, provide flexible, holistic care models, and expertly guide how the concept is adopted by primary care. While doing so, it is crucial to have a directory of culturally safe and responsive services, need assessment tools, and linking data on referrals and services to people to measure outcomes. Importantly, Australian academics, policy makers and the primary care sector should acknowledge this long history and learn from it by looking to Indigenous models of “social prescribing” that address the holistic needs of people to guide the implementation of social prescribing programs in Australia.

No relevant disclosures.

致编辑:为土著居民和托雷斯海峡岛民提供社区控制的初级保健服务的核心是全面综合的护理。为了实现这一目标,自 1971 年以来,土著居民和托雷斯海峡岛民社区控制的医疗机构(ACCHOs)一直在提供或联系使用这些服务的人们,通过植根于土著知识和习俗的关怀方式来解决各种社会经济和文化决定因素。1 除了生物医学和专职医疗转诊外,ACCHOs 还代理和提供一整套与住房、教育和法律援助服务相关的社会和文化联系。2 这种联系紧密的综合护理模式是 ACCHOs 的核心业务,它没有专门的名称。3 这些服务包括健康生活方式支持服务、经济援助、住房和社区园艺,最终将增进健康和幸福4。然而,ACCHO 模式一直在为患者和社区提供整体护理,其更可持续的劳动力模式需要在全国和全球范围内得到认可、赞美、复制和共享。5 这种以社会处方取代整体护理的做法再次证明了殖民者的持续殖民方式,土著居民和托雷斯海峡岛民的整体护理模式已被抹杀,并被重新构建为社会处方。人们很少承认,几十年来,社会处方一直在澳大利亚各地的 ACCHOs 中实施。必须开发一种全国性的资助模式,以充分支持 ACCHO 部门,提供灵活的整体护理模式,并以专业的方式指导初级保健如何采用这一概念。在此过程中,至关重要的是要建立一个文化上安全且顺应需求的服务目录、需求评估工具,并将转诊和服务数据与人们联系起来,以衡量结果。重要的是,澳大利亚学术界、政策制定者和初级医疗部门应承认这一悠久的历史,并从中汲取经验,借鉴满足人们整体需求的土著 "社会处方 "模式,以指导澳大利亚社会处方计划的实施。
{"title":"“Social prescribing” another stolen Indigenous concept?","authors":"Uday N Yadav,&nbsp;Rosemary Wyber,&nbsp;Fiona Cornforth (Wuthathi/Maluilgal),&nbsp;Raymond W Lovett (Wongaibon/Ngiyampaa)","doi":"10.5694/mja2.52413","DOIUrl":"10.5694/mja2.52413","url":null,"abstract":"<p><span>To the Editor:</span> Holistic comprehensive care is <i>the</i> core of community-controlled primary care services for Aboriginal and Torres Strait Islander peoples. To achieve this, Aboriginal and Torres Strait Islander community-controlled health organisations (ACCHOs) have routinely delivered or connected people using these services since 1971 to address the myriad of socio-economic and cultural determinants through a caring approach rooted in Indigenous knowledge and practices.<span><sup>1</sup></span> In addition to biomedical and allied health referrals, ACCHOs broker and provide a suite of social and cultural connections with housing, education and legal aid services.<span><sup>2</sup></span> This connected, comprehensive model of care is the core business of ACCHOs, and it does not have a special name.</p><p>Internationally, and in Australia, there is a growing focus on social prescribing programs. Social prescribing has been described as “pioneered” in the United Kingdom during the 1980s–1990s and provides a formal process for primary health care workers to connect patients to a wide range of non-clinical services and supports tailored to their needs.<span><sup>3</sup></span> These encompass healthy lifestyle support services, financial assistance, housing and community gardening, ultimately enhancing health and wellbeing.<span><sup>4</sup></span> There has been a surge in social prescribing research and policy interest globally. However, the ACCHO model has been delivering holistic care for patients and the community with a more sustainable workforce model that needs to be recognised, celebrated, replicated and shared nationally and globally.</p><p>A common feature of settler colonialism is the appropriation of lands, knowledge and concepts in the name of discovery.<span><sup>5</sup></span> This supplanting of holistic care with social prescribing is another demonstration of the continuing settler colonial approach, where the Aboriginal and Torres Strait Islander holistic model has been erased and reframed as social prescribing. There has been scant acknowledgement that social prescribing has been happening in ACCHOs across Australia for decades. A national funding model must be developed to adequately support the ACCHO sector, provide flexible, holistic care models, and expertly guide how the concept is adopted by primary care. While doing so, it is crucial to have a directory of culturally safe and responsive services, need assessment tools, and linking data on referrals and services to people to measure outcomes. Importantly, Australian academics, policy makers and the primary care sector should acknowledge this long history and learn from it by looking to Indigenous models of “social prescribing” that address the holistic needs of people to guide the implementation of social prescribing programs in Australia.</p><p>No relevant disclosures.</p>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52413","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141982748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sensitivity and specificity of Aboriginal-developed items to supplement the adapted PHQ-9 screening measure for depression: results from the Getting it Right study 土著人开发的项目对改编后的 PHQ-9 抑郁症筛查量表的敏感性和特异性:"正确对待 "研究的结果。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-08-14 DOI: 10.5694/mja2.52406
Timothy Skinner, Alex Brown, Armando Teixeira-Pinto, Sara F Farnbach, Nicholas Glozier, Deborah A Askew, Graham Gee, Alan Cass, Maree L Hackett

Objective

To determine the psychometric properties of an Aboriginal and Torres Strait Islander-developed depressive symptom screening scale.

Design

Prospective diagnostic accuracy study.

Setting

Ten primary health care services or residential alcohol and other drug rehabilitation services in Australia that predominantly serve Aboriginal and Torres Strait Islander peoples.

Participants

500 adults (18 years or older) who identified as Aboriginal and/or Torres Strait Islander and were able to communicate sufficiently to respond to questionnaire and interview questions. Recruitment occurred between 25 March 2015 and 2 November 2016.

Main outcome measure

Criterion validity of seven Aboriginal and Torres Strait Islander-developed items, using the adapted Patient Health Questionnaire 9 (aPHQ-9) and depression module of the Mini International Neuropsychiatric Interview (MINI) 6.0.0 as the criterion standards.

Results

The seven-item scale had good internal consistency (α = 0.83) and correlated highly with the aPHQ-9 (ρ = 0.76). All items were significantly associated with diagnosis of a current major depressive episode. Discriminant function and decision tree analysis identified three items forming a summed scale that classified 85% of participants correctly. These three items showed equivalent sensitivity and specificity to the aPHQ-9 when compared with the MINI-identified diagnosis of a current major depressive episode.

Conclusion

Three items developed by and for Aboriginal and Torres Strait Islander people may provide effective, efficient and culturally appropriate screening for depression in Aboriginal and Torres Strait Islander health care contexts.

目的:确定土著居民和托雷斯海峡岛民开发的抑郁症状筛查量表的心理测量特性:确定土著居民和托雷斯海峡岛民开发的抑郁症状筛查量表的心理测量特性:前瞻性诊断准确性研究:澳大利亚十家主要为土著居民和托雷斯海峡岛民服务的初级医疗保健服务机构或住院酒精和其他药物康复服务机构:500名成年人(18岁或以上),他们被认定为原住民和/或托雷斯海峡岛民,并能进行充分交流以回答问卷和访谈问题。招募时间为 2015 年 3 月 25 日至 2016 年 11 月 2 日:以改编后的患者健康问卷9(aPHQ-9)和迷你国际神经精神访谈(MINI)6.0.0抑郁模块为标准,对土著居民和托雷斯海峡岛民开发的七个项目进行标准效度测量:七项目量表具有良好的内部一致性(α = 0.83),与 aPHQ-9 高度相关(ρ = 0.76)。所有项目均与当前重度抑郁发作的诊断有明显相关。通过判别函数和决策树分析,确定了三个项目组成的总和量表,可将 85% 的参与者正确分类。这三个项目与 aPHQ-9 的灵敏度和特异性与 MINI 确定的当前重度抑郁发作诊断结果相当:结论:由土著居民和托雷斯海峡岛民开发的三个项目可为土著居民和托雷斯海峡岛民的医疗保健提供有效、高效且符合其文化背景的抑郁症筛查。
{"title":"Sensitivity and specificity of Aboriginal-developed items to supplement the adapted PHQ-9 screening measure for depression: results from the Getting it Right study","authors":"Timothy Skinner,&nbsp;Alex Brown,&nbsp;Armando Teixeira-Pinto,&nbsp;Sara F Farnbach,&nbsp;Nicholas Glozier,&nbsp;Deborah A Askew,&nbsp;Graham Gee,&nbsp;Alan Cass,&nbsp;Maree L Hackett","doi":"10.5694/mja2.52406","DOIUrl":"10.5694/mja2.52406","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To determine the psychometric properties of an Aboriginal and Torres Strait Islander-developed depressive symptom screening scale.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design</h3>\u0000 \u0000 <p>Prospective diagnostic accuracy study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Setting</h3>\u0000 \u0000 <p>Ten primary health care services or residential alcohol and other drug rehabilitation services in Australia that predominantly serve Aboriginal and Torres Strait Islander peoples.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Participants</h3>\u0000 \u0000 <p>500 adults (18 years or older) who identified as Aboriginal and/or Torres Strait Islander and were able to communicate sufficiently to respond to questionnaire and interview questions. Recruitment occurred between 25 March 2015 and 2 November 2016.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Main outcome measure</h3>\u0000 \u0000 <p>Criterion validity of seven Aboriginal and Torres Strait Islander-developed items, using the adapted Patient Health Questionnaire 9 (aPHQ-9) and depression module of the Mini International Neuropsychiatric Interview (MINI) 6.0.0 as the criterion standards.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The seven-item scale had good internal consistency (α = 0.83) and correlated highly with the aPHQ-9 (ρ = 0.76). All items were significantly associated with diagnosis of a current major depressive episode. Discriminant function and decision tree analysis identified three items forming a summed scale that classified 85% of participants correctly. These three items showed equivalent sensitivity and specificity to the aPHQ-9 when compared with the MINI-identified diagnosis of a current major depressive episode.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Three items developed by and for Aboriginal and Torres Strait Islander people may provide effective, efficient and culturally appropriate screening for depression in Aboriginal and Torres Strait Islander health care contexts.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52406","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141976100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Should medical eponyms continue to be used in everyday practice? 在日常实践中是否应继续使用医学同义词?
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-08-13 DOI: 10.5694/mja2.52416
Leya Nedumannil, Diana Lewis
<p>An eponymous term is an entity named after the person who first described, produced or performed it. In the medical world, eponyms have traditionally been a means of commemorating an individual's contribution towards their field of practice. Several arguments which support the preservation of eponyms exist, including that exceptional people deserve to have their achievements acknowledged, that these terms are well recognised in the medical community, and that eponyms possess educational value as a memory device for the learning and retention of complex medical concepts. For many, changing medical eponymous terms could represent an enormous feat potentially met with unwarranted confusion and, possibly, even indignance among traditionalists.</p><p>One key issue encompassing medical eponyms is their potential to falsely promote medical discoveries as the product of a single individual's efforts while neglecting the broader team that contributed. An example is Crohn disease, first described in an article that was actually co-authored by two additional medical practitioners, Oppenheimer and Ginzburg.<span><sup>1</sup></span> Medical progress is seldom a solo feat, and the use of eponyms may threaten important values of collaboration and collegiality in this realm.</p><p>Further, eponyms may reinforce the enduring issue of representation of women in medicine, or lack thereof. Numerous women have historically had their scientific achievements forgotten or inaccurately credited to men, a notion of systemic bias so widespread that it has ironically acquired an evocative eponymous title itself, named after suffragist Matilda Gage.<span><sup>2</sup></span> Indeed, women account for less than 4% of identified medical eponyms,<span><sup>3</sup></span> of which several are compound names shared with men, a stark reminder of the historical lack of opportunity there was for women to carve their name in the medical sphere. This is of particular relevance to current society with the recent striking release on the significant gender pay gap in Australia, including in medicine.<span><sup>4</sup></span></p><p>The unrestrained use of medical eponyms has also progressively come under scrutiny due to potentially glorifying the memory of individuals complicit in unethical methods of research historically veiled under the guise of scientific progress. Several articles quote the medical misconducts of the Nazi era as a reason to advocate for the removal of eponyms that honour physicians involved in crimes against humanity.<span><sup>5</sup></span> There has been a resultant change witnessed in the use of eponymous terms enshrouded by their dark past. An example is the replacement of Wegener granulomatosis with granulomatosis with polyangiitis, due to Friedrich Wegener's associations with the Nazi Party.<span><sup>6</sup></span></p><p>The liberal use of medical eponymous terms also places users at risk of inadvertently contributing to the persistence of colonialism and i
这不仅有助于将医学术语与几个同义词产生时的争议环境区分开来,还可能促进临床医生之间以及与患者之间更精确的交流。
{"title":"Should medical eponyms continue to be used in everyday practice?","authors":"Leya Nedumannil,&nbsp;Diana Lewis","doi":"10.5694/mja2.52416","DOIUrl":"10.5694/mja2.52416","url":null,"abstract":"&lt;p&gt;An eponymous term is an entity named after the person who first described, produced or performed it. In the medical world, eponyms have traditionally been a means of commemorating an individual's contribution towards their field of practice. Several arguments which support the preservation of eponyms exist, including that exceptional people deserve to have their achievements acknowledged, that these terms are well recognised in the medical community, and that eponyms possess educational value as a memory device for the learning and retention of complex medical concepts. For many, changing medical eponymous terms could represent an enormous feat potentially met with unwarranted confusion and, possibly, even indignance among traditionalists.&lt;/p&gt;&lt;p&gt;One key issue encompassing medical eponyms is their potential to falsely promote medical discoveries as the product of a single individual's efforts while neglecting the broader team that contributed. An example is Crohn disease, first described in an article that was actually co-authored by two additional medical practitioners, Oppenheimer and Ginzburg.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Medical progress is seldom a solo feat, and the use of eponyms may threaten important values of collaboration and collegiality in this realm.&lt;/p&gt;&lt;p&gt;Further, eponyms may reinforce the enduring issue of representation of women in medicine, or lack thereof. Numerous women have historically had their scientific achievements forgotten or inaccurately credited to men, a notion of systemic bias so widespread that it has ironically acquired an evocative eponymous title itself, named after suffragist Matilda Gage.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Indeed, women account for less than 4% of identified medical eponyms,&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; of which several are compound names shared with men, a stark reminder of the historical lack of opportunity there was for women to carve their name in the medical sphere. This is of particular relevance to current society with the recent striking release on the significant gender pay gap in Australia, including in medicine.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The unrestrained use of medical eponyms has also progressively come under scrutiny due to potentially glorifying the memory of individuals complicit in unethical methods of research historically veiled under the guise of scientific progress. Several articles quote the medical misconducts of the Nazi era as a reason to advocate for the removal of eponyms that honour physicians involved in crimes against humanity.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; There has been a resultant change witnessed in the use of eponymous terms enshrouded by their dark past. An example is the replacement of Wegener granulomatosis with granulomatosis with polyangiitis, due to Friedrich Wegener's associations with the Nazi Party.&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The liberal use of medical eponymous terms also places users at risk of inadvertently contributing to the persistence of colonialism and i","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52416","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141976101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A case of visceral leishmaniasis masquerading as autoimmune hepatitis 一例伪装成自身免疫性肝炎的内脏利什曼病。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-08-12 DOI: 10.5694/mja2.52412
Vinny Ea, Brigitte Papa, Rimma Goldberg
<p>A 72-year-old man with a history of well controlled type 2 diabetes was admitted to a tertiary metropolitan hospital for investigation of fevers, night sweats and unintentional weight loss of 18 kg over six months. He had pancytopenia with no symptoms or signs to suggest a focal infection, malignancy or rheumatological disease. Prior outpatient investigation findings revealed mild splenomegaly, with a normal bone marrow aspirate and positron emission tomography scan. At its nadir, the haemoglobin level was 106 g/L (reference interval [RI], 125–175 g/L), white cell count 1.9 × 10<sup>9</sup>/L (RI, 4.0–11.0 × 10<sup>9</sup>/L), neutrophil count 1.2 × 10<sup>9</sup>/L (RI, 2.00–8.00 × 10<sup>9</sup>/L) and platelets 120 × 10<sup>9</sup>/L (RI, 150–450 × 10<sup>9</sup>/L). Notably, liver function test results were mildly elevated in a mixed pattern with alkaline phosphatase 138 U/L (RI, 30–110 U/L), γ-glutamyl transferase 605 U/L (RI, 5–50 U/L) and alanine aminotransferase 78 U/L (RI, 5–40 U/L), with associated antinuclear antibody titre of more than 1280 (RI, < 160), and an elevated immunoglobulin G level of 38.6 g/L (RI, 7.5–15.6 g/L). Pertinent negative results included negative human immunodeficiency virus (HIV) and viral hepatitis serology, and negative anti-smooth muscle and anti-liver–kidney microsomal antibodies. Given these findings and the ongoing diagnostic dilemma, a liver biopsy was performed, showing mild interface hepatitis and lymphoplasmacytic infiltrate in the portal tracts (Box 1), and leading to a probable diagnosis of autoimmune hepatitis. Administration of azathioprine 25 mg and prednisolone 40 mg daily was initiated and the patient was discharged following improvement of his liver function test results.</p><p>The patient re-presented two weeks later due to worsening night sweats with no new localising symptoms and was found to have febrile neutropenia (neutrophil count, 0.4 × 10<sup>9</sup>/L). Administration of empiric antibiotics was started, and azathioprine was stopped due to possible contribution to worsening myelosuppression. As the patient was born in coastal Greece and had travelled there two years prior, leishmaniasis was raised as a differential diagnosis. A repeat bone marrow aspirate revealed <i>Leishmania</i> amastigotes under microscopy (Box 2) and polymerase chain reaction (PCR) testing was positive for <i>Leishmania donovani</i> complex. The patient was treated with intravenous liposomal amphotericin 3 mg/kg/dose on Days 1–5, Day 14 and Day 21, which led to resolution of symptoms and pancytopenia six weeks after treatment.</p><p>Visceral leishmaniasis is a vector-borne zoonotic disease primarily caused by parasites of the <i>L. donovani</i> complex (includes <i>L. donovani</i> and <i>Leishmania infantum</i>) and is transmitted via infected sandflies.<span><sup>1</sup></span> Globally, visceral leishmaniasis features on the World Health Organization list of neglected tropical diseases, with a significant b
一名 72 岁的男子因发烧、盗汗和半年来体重意外下降 18 公斤而被一家三级甲等医院收治,他曾患有控制良好的 2 型糖尿病。他患有全血细胞减少症,没有任何症状或体征表明他患有病灶感染、恶性肿瘤或风湿病。之前的门诊检查结果显示脾脏轻度肿大,骨髓穿刺和正电子发射断层扫描正常。血红蛋白水平最低时为 106 克/升(参考区间 [RI],125-175 克/升),白细胞计数为 1.9 × 109/升(参考区间,4.0-11.0 × 109/升),中性粒细胞计数为 1.2 × 109/升(参考区间,2.00-8.00 × 109/升),血小板为 120 × 109/升(参考区间,150-450 × 109/升)。值得注意的是,肝功能检测结果呈混合型轻度升高,碱性磷酸酶 138 U/L(RI,30-110 U/L),γ-谷氨酰转移酶 605 U/L(RI,5-50 U/L),丙氨酸氨基转移酶 78 U/L(RI,5-40 U/L),相关的抗核抗体滴度超过 1280(RI,&lt; 160),免疫球蛋白 G 水平升高至 38.6 g/L(RI,7.5-15.6 g/L)。相关阴性结果包括人类免疫缺陷病毒(HIV)和病毒性肝炎血清学阴性,抗平滑肌抗体和抗肝-肾微粒体抗体阴性。鉴于这些结果和持续存在的诊断难题,患者接受了肝活检,结果显示轻度界面性肝炎和门静脉淋巴浆细胞浸润(方框 1),可能诊断为自身免疫性肝炎。两周后,患者因盗汗加重再次就诊,但没有出现新的局部症状,并被发现患有发热性中性粒细胞减少症(中性粒细胞计数为 0.4 × 109/L)。医生开始使用经验性抗生素,并停用了硫唑嘌呤,因为这可能会导致骨髓抑制恶化。由于患者出生在希腊沿海地区,两年前曾到希腊旅行,因此利什曼病被列为鉴别诊断。再次进行骨髓穿刺后,显微镜下发现了利什曼原虫(方框 2),聚合酶链反应(PCR)检测显示多诺万利什曼原虫复合体呈阳性。患者在第 1-5 天、第 14 天和第 21 天接受了 3 毫克/千克/剂量的静脉注射脂质体两性霉素治疗,治疗六周后症状和泛发性红细胞减少。内脏利什曼病是一种病媒传播的人畜共患疾病,主要由多诺万利什曼复合体(包括多诺万利什曼和婴儿利什曼)寄生虫引起,通过受感染的沙蝇传播。在全球范围内,内脏利什曼病被世界卫生组织列入被忽视的热带疾病名单,在热带和亚热带地区,包括北非、南美、西亚、南欧和地中海地区造成了严重的负担。4 并发症包括出血、肝功能障碍、中性粒细胞感染、播散性血管内凝血和嗜血细胞淋巴组织细胞增多症。5 潜伏期通常为数月,但也可能从几周到数年不等。在本病例中,患者两年内没有去过希腊或其他流行地区,这说明潜伏期较长。传统上,内脏利什曼病的明确诊断需要在骨髓或脾脏抽吸物的组织涂片上看到寄生虫。然而,灵敏度取决于彻底的微生物学检查,6 而且活检可能涉及脾大出血等手术风险,尤其是考虑到内脏利什曼病的出血倾向增加。另外,用 PCR 对外周血、骨髓和脾组织进行分子检测也很灵敏,在一些研究中超过了微生物检查7 ,但这种方法仅限于专业实验室。使用 rK39 抗原进行血清学诊断也具有合理的灵敏度。在流行地区,PCR 和血清学检测的特异性可能较低,因为亚临床携带者和治疗病例可能会出现阳性结果。 8 此外,免疫功能低下的患者对利什曼病没有血清学反应,血清学的价值有限,但这并不影响 PCR 检测。总之,在非流行区,PCR 检测加上辅助临床和流行病学特征是一种合适的诊断方法。在该患者中,内脏利什曼病的诊断被最初的自身免疫性肝炎诊断所混淆。文献曾描述过内脏利什曼病与自身抗体、高丙种球蛋白血症和模仿自身免疫性肝炎的组织病理学特征之间的关联。9, 10 建议的机制包括寄生虫对组织的破坏导致组织抗原释放,诱发自身反应,产生自身抗体;内脏利什曼病刺激多克隆 B 细胞活化,导致高丙种球蛋白血症。由于这些免疫现象,内脏利什曼病也被证明可模拟其他自身免疫性疾病,包括系统性红斑狼疮。内脏利什曼病的治疗因药物的敏感性、可获得性和成本而因地区而异,在资源丰富的国家,脂质体两性霉素 B 是首选药物,因为它具有卓越的抗菌效果和安全性。对于免疫力低下的患者,还需要进一步考虑治疗问题,尤其是艾滋病毒-唐诺瓦尼复合感染患者,因为在这种情况下,细胞免疫力会被耗尽,如果不进行免疫重建,抗菌治疗可能会不充分。12 总之,内脏利什曼病在澳大利亚很少发现,仍然是原因不明的泛发性和热病的罕见鉴别诊断。莫纳什大学通过澳大利亚大学图书馆员理事会达成了 Wiley - 莫纳什大学协议,该协议为莫纳什大学的开放存取出版提供了便利,患者已书面同意发表该论文。
{"title":"A case of visceral leishmaniasis masquerading as autoimmune hepatitis","authors":"Vinny Ea,&nbsp;Brigitte Papa,&nbsp;Rimma Goldberg","doi":"10.5694/mja2.52412","DOIUrl":"10.5694/mja2.52412","url":null,"abstract":"&lt;p&gt;A 72-year-old man with a history of well controlled type 2 diabetes was admitted to a tertiary metropolitan hospital for investigation of fevers, night sweats and unintentional weight loss of 18 kg over six months. He had pancytopenia with no symptoms or signs to suggest a focal infection, malignancy or rheumatological disease. Prior outpatient investigation findings revealed mild splenomegaly, with a normal bone marrow aspirate and positron emission tomography scan. At its nadir, the haemoglobin level was 106 g/L (reference interval [RI], 125–175 g/L), white cell count 1.9 × 10&lt;sup&gt;9&lt;/sup&gt;/L (RI, 4.0–11.0 × 10&lt;sup&gt;9&lt;/sup&gt;/L), neutrophil count 1.2 × 10&lt;sup&gt;9&lt;/sup&gt;/L (RI, 2.00–8.00 × 10&lt;sup&gt;9&lt;/sup&gt;/L) and platelets 120 × 10&lt;sup&gt;9&lt;/sup&gt;/L (RI, 150–450 × 10&lt;sup&gt;9&lt;/sup&gt;/L). Notably, liver function test results were mildly elevated in a mixed pattern with alkaline phosphatase 138 U/L (RI, 30–110 U/L), γ-glutamyl transferase 605 U/L (RI, 5–50 U/L) and alanine aminotransferase 78 U/L (RI, 5–40 U/L), with associated antinuclear antibody titre of more than 1280 (RI, &lt; 160), and an elevated immunoglobulin G level of 38.6 g/L (RI, 7.5–15.6 g/L). Pertinent negative results included negative human immunodeficiency virus (HIV) and viral hepatitis serology, and negative anti-smooth muscle and anti-liver–kidney microsomal antibodies. Given these findings and the ongoing diagnostic dilemma, a liver biopsy was performed, showing mild interface hepatitis and lymphoplasmacytic infiltrate in the portal tracts (Box 1), and leading to a probable diagnosis of autoimmune hepatitis. Administration of azathioprine 25 mg and prednisolone 40 mg daily was initiated and the patient was discharged following improvement of his liver function test results.&lt;/p&gt;&lt;p&gt;The patient re-presented two weeks later due to worsening night sweats with no new localising symptoms and was found to have febrile neutropenia (neutrophil count, 0.4 × 10&lt;sup&gt;9&lt;/sup&gt;/L). Administration of empiric antibiotics was started, and azathioprine was stopped due to possible contribution to worsening myelosuppression. As the patient was born in coastal Greece and had travelled there two years prior, leishmaniasis was raised as a differential diagnosis. A repeat bone marrow aspirate revealed &lt;i&gt;Leishmania&lt;/i&gt; amastigotes under microscopy (Box 2) and polymerase chain reaction (PCR) testing was positive for &lt;i&gt;Leishmania donovani&lt;/i&gt; complex. The patient was treated with intravenous liposomal amphotericin 3 mg/kg/dose on Days 1–5, Day 14 and Day 21, which led to resolution of symptoms and pancytopenia six weeks after treatment.&lt;/p&gt;&lt;p&gt;Visceral leishmaniasis is a vector-borne zoonotic disease primarily caused by parasites of the &lt;i&gt;L. donovani&lt;/i&gt; complex (includes &lt;i&gt;L. donovani&lt;/i&gt; and &lt;i&gt;Leishmania infantum&lt;/i&gt;) and is transmitted via infected sandflies.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Globally, visceral leishmaniasis features on the World Health Organization list of neglected tropical diseases, with a significant b","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52412","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding modelled economic evaluations: a reader's guide for clinicians 了解经济评价模型:临床医生读者指南》。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-08-09 DOI: 10.5694/mja2.52409
Winnie Chen, Martin Howell, Alan Cass, Gillian Gorham, Kirsten Howard
<p>Economic evaluations have a long history in health care.<span><sup>1, 2</sup></span> Full economic evaluations aim to inform decision making through comparing the costs and outcomes of two or more interventions, strategies, programs or policies, to estimate their efficiency via an incremental cost-effectiveness ratio. The premise for conducting economic evaluations is that health care resources are finite, and there is an opportunity cost when resources are allocated to one health care intervention over another.<span><sup>3, 4</sup></span> In Australia, economic evaluations are important considerations in policy decisions on what should be publicly funded under the Pharmaceutical Benefits Scheme (PBS)<span><sup>5</sup></span> and Medicare Benefits Schedule (MBS).<span><sup>6</sup></span> Furthermore, clinician–researchers are increasingly considering both clinical effectiveness and cost-effectiveness in evaluation studies and funding applications.</p><p>Full economic evaluations are classified by the type of evaluation, with the most common types being cost-effectiveness analysis (CEA), cost–utility analysis (CUA) and cost–benefit analysis (CBA).<span><sup>3</sup></span> The method for conducting these economic evaluations can be study-based or decision–analytic model-based, or both.<span><sup>7</sup></span> Modelled economic evaluations can overcome some of the limitations associated with study-based economic evaluations.<span><sup>7, 8</sup></span> The complexity and use of modelled evaluations has increased with improved computing power and data availability. Several published articles offer clinicians an introduction to economic evaluations,<span><sup>1, 9, 10</sup></span> but few to date have focused on modelled evaluations.<span><sup>11, 12</sup></span> In this key research skills article, we aim to improve clinician understanding of modelled evaluations. In the Supporting Information, we illustrate key modelling concepts using two recently published models in the <i>Medical Journal of Australia</i>.</p><p>Why are model-based evaluations done? Modelled evaluations can be performed alongside empiric studies or as standalone studies. Modelled evaluations do not replace study-based evaluations — rather, they enable evidence synthesis across multiple studies into relevant decision-making contexts, extrapolation of trial-based results beyond the time horizon, and hypothesis generation where data are unavailable.<span><sup>7, 8, 13</sup></span> Box 1 outlines key areas in which study-based and model-based economic evaluations differ.</p><p>We use an example of a randomised controlled trial (RCT) calculating the cost-effectiveness of a new blood pressure medicine compared with placebo to illustrate why modelled evaluations might be required. Firstly, the model can be used to synthesise evidence across multiple trials for decision making.<span><sup>8</sup></span> Whereas the RCT is only comparing the new medicine against the placebo, a modelled
8 例如,参数的不确定性可能以平均值的标准差或置信区间的形式出现;也可能因参数值的多种文献估计值而产生。确定性敏感性分析包括单向、双向和多向敏感性分析,这些分析涉及改变一个或多个参数的输入,并观察这些变化对成本、结果和 ICER 的影响。19 例如,在方框 5 中,心血管疾病患者的死亡概率为 5%。单向敏感性分析可研究当使用 3% 至 7% 的替代概率而不是 5%时,ICER 会发生怎样的变化。确定性敏感性分析有助于确定哪些参数对成本、健康结果和成本效益的影响最大,以及 ICER 是否会随着参数的变化从具有成本效益到不具有成本效益而变化。如果我们对方框 5 中的马尔可夫队列模型进行 PSA,参数(概率、成本、结果)将以分布而非固定值的形式输入。例如,我们现在输入的死亡概率是平均值为 0.05 的分布,而不是输入心血管疾病患者每年 5%的死亡概率。然后多次运行模型(如运行 1000 次),每次都从该分布中选择一个新的过渡概率值。从外观上看,PSA 结果可以绘制在成本效益平面上,每次运行的 ICER 表示为一个点(方框 7)。方框 7 中的对角虚线代表每 QALY 50 000 美元的任意支付意愿阈值。红点代表高于支付意愿阈值(被认为不具成本效益)的每次运行,绿点代表低于支付意愿阈值(被认为具有成本效益)的每次运行。较大的绿色圆圈代表每 QALY 75 742 美元的估计 ICER 周围 95% 的置信区间。我们将对经济评价模型的理解应用到已发表的模型中,以 2023 年发表在《澳大利亚医学杂志》上的两篇文章为例。Xiao 及其同事的马尔可夫队列模型研究了慢性乙型肝炎筛查策略与常规护理的成本效益。20 Venkataraman 及其同事的马尔可夫微观模拟模型研究了几种基于风险评分和冠状动脉钙化评分的他汀类药物治疗起始策略的成本效益。本表旨在强调关键概念,而不是应用相关的关键评估工具,如 CHEERS(卫生经济学评估综合报告标准)或类似工具。我们鼓励对卫生经济学感兴趣的读者获取深度资源,其中包括如何构建模型的工作示例。
{"title":"Understanding modelled economic evaluations: a reader's guide for clinicians","authors":"Winnie Chen,&nbsp;Martin Howell,&nbsp;Alan Cass,&nbsp;Gillian Gorham,&nbsp;Kirsten Howard","doi":"10.5694/mja2.52409","DOIUrl":"10.5694/mja2.52409","url":null,"abstract":"&lt;p&gt;Economic evaluations have a long history in health care.&lt;span&gt;&lt;sup&gt;1, 2&lt;/sup&gt;&lt;/span&gt; Full economic evaluations aim to inform decision making through comparing the costs and outcomes of two or more interventions, strategies, programs or policies, to estimate their efficiency via an incremental cost-effectiveness ratio. The premise for conducting economic evaluations is that health care resources are finite, and there is an opportunity cost when resources are allocated to one health care intervention over another.&lt;span&gt;&lt;sup&gt;3, 4&lt;/sup&gt;&lt;/span&gt; In Australia, economic evaluations are important considerations in policy decisions on what should be publicly funded under the Pharmaceutical Benefits Scheme (PBS)&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; and Medicare Benefits Schedule (MBS).&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; Furthermore, clinician–researchers are increasingly considering both clinical effectiveness and cost-effectiveness in evaluation studies and funding applications.&lt;/p&gt;&lt;p&gt;Full economic evaluations are classified by the type of evaluation, with the most common types being cost-effectiveness analysis (CEA), cost–utility analysis (CUA) and cost–benefit analysis (CBA).&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; The method for conducting these economic evaluations can be study-based or decision–analytic model-based, or both.&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; Modelled economic evaluations can overcome some of the limitations associated with study-based economic evaluations.&lt;span&gt;&lt;sup&gt;7, 8&lt;/sup&gt;&lt;/span&gt; The complexity and use of modelled evaluations has increased with improved computing power and data availability. Several published articles offer clinicians an introduction to economic evaluations,&lt;span&gt;&lt;sup&gt;1, 9, 10&lt;/sup&gt;&lt;/span&gt; but few to date have focused on modelled evaluations.&lt;span&gt;&lt;sup&gt;11, 12&lt;/sup&gt;&lt;/span&gt; In this key research skills article, we aim to improve clinician understanding of modelled evaluations. In the Supporting Information, we illustrate key modelling concepts using two recently published models in the &lt;i&gt;Medical Journal of Australia&lt;/i&gt;.&lt;/p&gt;&lt;p&gt;Why are model-based evaluations done? Modelled evaluations can be performed alongside empiric studies or as standalone studies. Modelled evaluations do not replace study-based evaluations — rather, they enable evidence synthesis across multiple studies into relevant decision-making contexts, extrapolation of trial-based results beyond the time horizon, and hypothesis generation where data are unavailable.&lt;span&gt;&lt;sup&gt;7, 8, 13&lt;/sup&gt;&lt;/span&gt; Box 1 outlines key areas in which study-based and model-based economic evaluations differ.&lt;/p&gt;&lt;p&gt;We use an example of a randomised controlled trial (RCT) calculating the cost-effectiveness of a new blood pressure medicine compared with placebo to illustrate why modelled evaluations might be required. Firstly, the model can be used to synthesise evidence across multiple trials for decision making.&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt; Whereas the RCT is only comparing the new medicine against the placebo, a modelled ","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52409","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141913178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overcoming disparities in hepatocellular carcinoma outcomes in First Nations Australians: a strategic plan for action 克服澳大利亚原住民肝细胞癌结果的差异:一项战略行动计划。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-08-06 DOI: 10.5694/mja2.52395
Jessica Howell, Troy Combo, Paula Binks, Kylie Bragg, Sarah Bukulatjpi, Kirsty Campbell, Paul J Clark, Melissa Carroll, Jane Davies, Teresa de Santis, Kate R Muller, Bella Nguyen, John K Olynyk, Nicholas Shackel, Patricia C Valery, Alan J Wigg, Jacob George, Stuart K Roberts
<p>Every year, about 1800 Australians die of hepatocellular carcinoma (HCC), the most common type of primary liver cancer.<span><sup>1</sup></span></p><p>Aboriginal and Torres Strait Islander peoples of Australia (hereon respectfully referred to as First Nations Australians) are 2.5 times more likely to develop HCC and 1.4 times more likely to die from HCC than non-Indigenous Australians.<span><sup>2</sup></span></p><p>First Nations Australians with HCC have a 9% five-year survival rate compared with 23% for non-Indigenous Australians,<span><sup>2</sup></span> and are half as likely to be diagnosed with early-stage HCC and receive curative therapy.<span><sup>2</sup></span> This is driven by First Nations Australians being adversely affected by social, cultural and commercial determinants of health stemming from colonisation, racism and remoteness.<span><sup>3</sup></span></p><p>Chronic liver disease is the key cause of HCC and most chronic liver disease is preventable and treatable.<span><sup>4, 5</sup></span> First Nations Australians shoulder a disproportionate burden of chronic liver disease (Box 1).<span><sup>6</sup></span> Alcohol-related liver disease is a leading cause of HCC in all Australians, including First Nations Australians.<span><sup>2, 7, 8</sup></span> The prevalence of hepatitis B and C is two- to three-fold higher in First Nations Australians compared with non-Indigenous Australians.<span><sup>2, 5</sup></span> The most prevalent hepatitis B genotype in remote First Nations communities (genotype C4) is associated with more aggressive liver disease and increased HCC risk compared with other genotypes.<span><sup>9, 10</sup></span> Obesity and type 2 diabetes, both leading risk factors for metabolic-associated fatty liver disease, are twice as common in First Nations Australians than in non-Indigenous Australians.<span><sup>3</sup></span> Importantly, First Nations Australians are more likely to have multiple cofactors driving liver injury,<span><sup>2</sup></span> warranting a multipronged approach to HCC prevention.</p><p>The two lead authors of this article, one First Nations Australian and one non-Indigenous Australian, established a nationally representative, diverse group of four First Nations Australian and 14 non-Indigenous Australian clinical and research leaders in the fields of HCC and chronic liver disease for the project. All authors have expertise in the provision of regional or remote models of HCC or chronic liver disease care, or both. First, an initial two-hour virtual meeting was held, where authors shared their thoughts and responses to two main topics: i) identifying unmet needs in prevention, diagnosis and treatment of HCC in First Nations Australians; and ii) identifying opportunities to address these unmet needs. All authors shared key evidence and their experiences and perspectives, representing the differing epidemiology, health resourcing, policy and legislative contexts across all Australian states and
每年约有 1800 名澳大利亚人死于肝细胞癌(HCC),这是最常见的原发性肝癌类型。1 澳大利亚原住民和托雷斯海峡岛民(以下尊称为 "澳大利亚原住民")罹患 HCC 的几率是非澳大利亚原住民的 2.5 倍,死于 HCC 的几率是非澳大利亚原住民的 1.4 倍。2 患有 HCC 的澳大利亚原住民的五年存活率为 9%,而非澳大利亚原住民的五年存活率为 23%,2 而且被诊断为早期 HCC 并接受根治性治疗的几率只有非澳大利亚原住民的一半。3慢性肝病是导致HCC的主要原因,而大多数慢性肝病是可以预防和治疗的。4, 5澳大利亚原住民承受着不成比例的慢性肝病负担(方框1)、偏远原住民社区最普遍的乙型肝炎基因型(基因型 C4)与其他基因型相比,与更严重的肝病和更高的 HCC 风险相关。本文的两位主要作者(一位是澳大利亚原住民,一位是非澳大利亚原住民)为该项目成立了一个具有全国代表性的多元化小组,成员包括 4 位澳大利亚原住民和 14 位非澳大利亚原住民,他们都是 HCC 和慢性肝病领域的临床和研究带头人。所有作者都拥有提供地区或偏远地区 HCC 或慢性肝病护理模式或两者兼有的专业知识。首先,我们召开了一次两小时的首次虚拟会议,作者们在会上就两个主要议题交流了想法并做出了回应:i)确定澳大利亚原住民在预防、诊断和治疗 HCC 方面尚未满足的需求;ii)确定满足这些未满足需求的机会。所有作者都分享了关键证据及其经验和观点,代表了澳大利亚各州和地区不同的流行病学、卫生资源、政策和立法背景。在讨论的基础上,主要作者采用积极的循证方法,优先考虑原住民主导的干预措施和护理模式,制定了一份包含八个关键行动项目的清单。作为原住民和非原住民卫生工作者及 HCC 研究人员的全国性合作,我们确定了八项关键行动措施(如下所示),这些措施将有助于解决澳大利亚原住民 HCC 发病率和死亡率的差异问题,应立即优先进行投资(方框 2、方框 3 和方框 4)。尽管澳大利亚原住民的 HCC 患病率和死亡率仍然高得令人无法接受,但由澳大利亚原住民共同领导的成功计划所提供的数据为实现 HCC 治疗结果的更大平等带来了新的希望。杰西卡-豪厄尔(Jessica Howell)曾为卫材、阿斯利康、罗氏和吉利德公司收取演讲费并参加顾问委员会;还曾获得吉利德科学公司和卫材公司的竞争性资助。Troy Combo 曾担任阿斯利康公司顾问委员会成员。Paula Binks 曾加入卫材和阿斯利康的顾问委员会。Kylie Bragg 曾担任阿斯利康公司顾问委员会成员。凯特-穆勒(Kate Muller)参加过阿斯利康公司的顾问委员会。艾伦-维格曾参加过卫材公司的顾问委员会。雅各布-乔治曾参加诺和诺德、阿斯利康、罗氏、BMS、辉瑞、Cincera、Pharmaxis、勃林格曼海姆等公司的顾问委员会,并从这些公司获得讲座酬金。斯图尔特-罗伯茨曾参加卫材、阿斯利康和罗氏的顾问委员会。
{"title":"Overcoming disparities in hepatocellular carcinoma outcomes in First Nations Australians: a strategic plan for action","authors":"Jessica Howell,&nbsp;Troy Combo,&nbsp;Paula Binks,&nbsp;Kylie Bragg,&nbsp;Sarah Bukulatjpi,&nbsp;Kirsty Campbell,&nbsp;Paul J Clark,&nbsp;Melissa Carroll,&nbsp;Jane Davies,&nbsp;Teresa de Santis,&nbsp;Kate R Muller,&nbsp;Bella Nguyen,&nbsp;John K Olynyk,&nbsp;Nicholas Shackel,&nbsp;Patricia C Valery,&nbsp;Alan J Wigg,&nbsp;Jacob George,&nbsp;Stuart K Roberts","doi":"10.5694/mja2.52395","DOIUrl":"10.5694/mja2.52395","url":null,"abstract":"&lt;p&gt;Every year, about 1800 Australians die of hepatocellular carcinoma (HCC), the most common type of primary liver cancer.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Aboriginal and Torres Strait Islander peoples of Australia (hereon respectfully referred to as First Nations Australians) are 2.5 times more likely to develop HCC and 1.4 times more likely to die from HCC than non-Indigenous Australians.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;First Nations Australians with HCC have a 9% five-year survival rate compared with 23% for non-Indigenous Australians,&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; and are half as likely to be diagnosed with early-stage HCC and receive curative therapy.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; This is driven by First Nations Australians being adversely affected by social, cultural and commercial determinants of health stemming from colonisation, racism and remoteness.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Chronic liver disease is the key cause of HCC and most chronic liver disease is preventable and treatable.&lt;span&gt;&lt;sup&gt;4, 5&lt;/sup&gt;&lt;/span&gt; First Nations Australians shoulder a disproportionate burden of chronic liver disease (Box 1).&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; Alcohol-related liver disease is a leading cause of HCC in all Australians, including First Nations Australians.&lt;span&gt;&lt;sup&gt;2, 7, 8&lt;/sup&gt;&lt;/span&gt; The prevalence of hepatitis B and C is two- to three-fold higher in First Nations Australians compared with non-Indigenous Australians.&lt;span&gt;&lt;sup&gt;2, 5&lt;/sup&gt;&lt;/span&gt; The most prevalent hepatitis B genotype in remote First Nations communities (genotype C4) is associated with more aggressive liver disease and increased HCC risk compared with other genotypes.&lt;span&gt;&lt;sup&gt;9, 10&lt;/sup&gt;&lt;/span&gt; Obesity and type 2 diabetes, both leading risk factors for metabolic-associated fatty liver disease, are twice as common in First Nations Australians than in non-Indigenous Australians.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Importantly, First Nations Australians are more likely to have multiple cofactors driving liver injury,&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; warranting a multipronged approach to HCC prevention.&lt;/p&gt;&lt;p&gt;The two lead authors of this article, one First Nations Australian and one non-Indigenous Australian, established a nationally representative, diverse group of four First Nations Australian and 14 non-Indigenous Australian clinical and research leaders in the fields of HCC and chronic liver disease for the project. All authors have expertise in the provision of regional or remote models of HCC or chronic liver disease care, or both. First, an initial two-hour virtual meeting was held, where authors shared their thoughts and responses to two main topics: i) identifying unmet needs in prevention, diagnosis and treatment of HCC in First Nations Australians; and ii) identifying opportunities to address these unmet needs. All authors shared key evidence and their experiences and perspectives, representing the differing epidemiology, health resourcing, policy and legislative contexts across all Australian states and ","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52395","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Medical Journal of Australia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1